PDF(Pubmed)
Abstract：
UNASSIGNED: Allergic rhinoconjunctivitis (AR) is an IgE-mediated inflammation of nasal and ocular mucosa after environmental allergen exposure, mainly by house dust mites (HDM). AR affects more than one third of the population worldwide and it is associated with loss of quality of life (QoL).
UNASSIGNED: To analyse the improvement in the QoL in 50 patients with moderate-persistent AR due to house HDM before and after receiving 1 year of subcutaneous specific aeroallergen immunotherapy treatment (SAIT).
UNASSIGNED: A prospective observational study was performed based on clinical practice in 50 patients with moderate-severe persistent AR due to HDM and candidates to SAIT. Forty-one patients completed the study. Patients were evaluated with the ESPRINT short-version QoL questionnaire, a score of medication use and visual analogue scale (VAS) symptom score, prior to and 12 months after SAIT.
UNASSIGNED: Forty-one patients (25 women, mean age 26.9 years). Mean ESPRINT values prior to the start SAIT was 3.06 (moderate-severe) and 1 year after starting subcutaneous SAIT the mean value dropped in all patients to 0.88 (mild). The VAS score symptom dropped from 8.26 to 3.68. 97.56% of patients used 3 or more drugs (oral antihistamine, ophthalmic/intranasal antihistamine, intranasal corticosteroid and/or oral antileukotrienes) prior to starting SAIT, and 1 year after it, 58.53% used one on-demand medication to control symptoms, oral antihistamine or nasal spray, and not daily use.
UNASSIGNED: Subcutaneous SAIT seems to be a valid treatment in our patients with moderate-persistent AR due to HDM, since it reduces the ESPRINT score, VAS score and the use of medication. An improvement in the quality of life and satisfaction was observed by the patients themselves.
UNASSIGNED: To analyse the improvement in the QoL in 50 patients with moderate-persistent AR due to house HDM before and after receiving 1 year of subcutaneous specific aeroallergen immunotherapy treatment (SAIT).
UNASSIGNED: A prospective observational study was performed based on clinical practice in 50 patients with moderate-severe persistent AR due to HDM and candidates to SAIT. Forty-one patients completed the study. Patients were evaluated with the ESPRINT short-version QoL questionnaire, a score of medication use and visual analogue scale (VAS) symptom score, prior to and 12 months after SAIT.
UNASSIGNED: Forty-one patients (25 women, mean age 26.9 years). Mean ESPRINT values prior to the start SAIT was 3.06 (moderate-severe) and 1 year after starting subcutaneous SAIT the mean value dropped in all patients to 0.88 (mild). The VAS score symptom dropped from 8.26 to 3.68. 97.56% of patients used 3 or more drugs (oral antihistamine, ophthalmic/intranasal antihistamine, intranasal corticosteroid and/or oral antileukotrienes) prior to starting SAIT, and 1 year after it, 58.53% used one on-demand medication to control symptoms, oral antihistamine or nasal spray, and not daily use.
UNASSIGNED: Subcutaneous SAIT seems to be a valid treatment in our patients with moderate-persistent AR due to HDM, since it reduces the ESPRINT score, VAS score and the use of medication. An improvement in the quality of life and satisfaction was observed by the patients themselves.
摘要：
■过敏性鼻结膜炎（AR）是环境过敏原暴露后由IgE介导的鼻和眼粘膜炎症，主要由屋尘螨（HDM）。AR影响全球超过三分之一的人口，并且与生活质量（QoL）的丧失有关。
■分析50例中度持续性AR患者在接受1年皮下特异性空气变应原免疫疗法治疗（SAIT）之前和之后因houseHDM导致的QoL改善。
■根据临床实践，对50例因HDM和SAIT候选的中重度持续性AR患者进行了一项前瞻性观察性研究。41名患者完成了研究。使用ESPRINT简短版本的QoL问卷对患者进行评估，药物使用评分和视觉模拟评分（VAS）症状评分，在SAIT之前和之后12个月。
■41名患者（25名女性，平均年龄26.9岁)。开始SAIT之前的平均ESPRINT值为3.06（中度-重度），开始皮下SAIT后1年，所有患者的平均值均降至0.88（轻度）。VAS评分症状从8.26降至3.68。97.56%的患者使用了3种或更多的药物（口服抗组胺药，眼科/鼻内抗组胺药，在开始SAIT之前，鼻内皮质类固醇和/或口服抗白三烯），一年后，58.53％使用一种按需药物来控制症状，口服抗组胺药或鼻腔喷雾剂，而不是日常使用。
■皮下SAIT似乎是我们由于HDM导致中度持续性AR患者的有效治疗方法，因为它降低了ESPRINT得分，VAS评分和用药情况。患者自身观察到生活质量和满意度的改善。
■分析50例中度持续性AR患者在接受1年皮下特异性空气变应原免疫疗法治疗（SAIT）之前和之后因houseHDM导致的QoL改善。
■根据临床实践，对50例因HDM和SAIT候选的中重度持续性AR患者进行了一项前瞻性观察性研究。41名患者完成了研究。使用ESPRINT简短版本的QoL问卷对患者进行评估，药物使用评分和视觉模拟评分（VAS）症状评分，在SAIT之前和之后12个月。
■41名患者（25名女性，平均年龄26.9岁)。开始SAIT之前的平均ESPRINT值为3.06（中度-重度），开始皮下SAIT后1年，所有患者的平均值均降至0.88（轻度）。VAS评分症状从8.26降至3.68。97.56%的患者使用了3种或更多的药物（口服抗组胺药，眼科/鼻内抗组胺药，在开始SAIT之前，鼻内皮质类固醇和/或口服抗白三烯），一年后，58.53％使用一种按需药物来控制症状，口服抗组胺药或鼻腔喷雾剂，而不是日常使用。
■皮下SAIT似乎是我们由于HDM导致中度持续性AR患者的有效治疗方法，因为它降低了ESPRINT得分，VAS评分和用药情况。患者自身观察到生活质量和满意度的改善。
